Normunity

👥 23 employees💰 Last funded Dec 2025
Biotechnology🌐 normunity.com
Website LinkedIn
Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company’s lead program, NRM‑823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025. Normunity is located in Boston, MA, and New Haven, CT.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Normunity?
Normunity has 2 investors on record on gritt.io.
When did Normunity last raise funding?
The most recent investment in Normunity recorded on gritt.io was in December 2025.
What industry is Normunity in?
Normunity operates in Biotechnology. Find similar Biotechnology investors on gritt.io.